Navigation Links
Intercept Pharmaceuticals to Present at the Wedbush Securities Life Sciences Management Access Conference
Date:8/5/2013

NEW YORK, Aug. 5, 2013 /PRNewswire/ -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, such as primary biliary cirrhosis, today announced that Mark Pruzanski, MD, President and Chief Executive Officer, will present at the Wedbush Securities Life Sciences Management Access Conference in New York on Tuesday, August 13, 2013 at 9:45 a.m. ET.  A live webcast of the company's presentation will be available on the "Events" section of Intercept's investor website at http://ir.interceptpharma.com. A replay of the presentation will also be archived and available on Intercept's website for 2 weeks.

About Intercept

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat orphan and more prevalent liver diseases, such as primary biliary cirrhosis, utilizing its expertise in bile acid chemistry. The company's lead product candidate, obeticholic acid (OCA) is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR). OCA is initially being developed for the second line treatment of primary biliary cirrhosis (PBC) in patients with an inadequate response to, or who are unable to tolerate, ursodiol, the only approved therapy for this indication. OCA has received orphan drug designation in both the United States and Europe for the treatment of PBC. Intercept owns worldwide rights to OCA outside of Japan and China, where it has out-licensed the product candidate to DSP. For more information about Intercept, please visit the Company's website at: www.interceptpharma.com.


'/>"/>
SOURCE Intercept Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock
2. Intercept Pharmaceuticals Announces Proposed Public Offering of Common Stock
3. Intercept Pharmaceuticals to Present at Deutsche Bank Healthcare Conference
4. Intercept Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
5. Intercept Pharmaceuticals Closes $30 Million Series C Financing
6. GW Pharmaceuticals Announces Results of MS Spasticity Study Confirming Sativex Has No Long-Term Negative Effect on Cognition
7. GW Pharmaceuticals plc Reports 2013 Third Quarter Financial Results
8. AcelRx Pharmaceuticals to Hold Second Quarter 2013 Financial Results Conference Call and Webcast on August 12, 2013
9. Radiopharmaceuticals Market - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 - 2018
10. OPTIMER PHARMACEUTICALS SHAREHOLDER ALERT: Levi & Korsinsky Investigates Possible Breaches of Fiduciary Duty by Board of Optimer Pharmaceuticals, Inc. in Connection with Sale of Company to Cubist Pharmaceuticals, Inc.
11. Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... Jan. 24, 2017   Keneric Healthcare , ... cost effective patient care products, today announced their ... expand the reach of both companies by leveraging ... expertise. Angelini Pharma Inc ... now include Keneric Healthcare,s RTD™ Wound Dressing (antibacterial/antifungal). ...
(Date:1/24/2017)... , January 24, 2017 Stock-Callers.com ... Zoetis Inc. (NYSE: ZTS ), Mallinckrodt PLC (NYSE: ... ), and Diplomat Pharmacy Inc. (NYSE: DPLO ). ... for significant change in 2017 for the Generic Drugs industry, ... because of the industry,s current growth, and a speedier FDA ...
(Date:1/24/2017)... -- Laboratory Markets Limited has completed a comprehensive market ... both clinical and research laboratory settings. This study, which ... $6.8 billion and growing to $9.2 billion (CAGR of ... of mass spectrometry across more than 5,200 clinical and ... in the use of mass spectrometry in terms of ...
Breaking Medicine Technology:
(Date:1/24/2017)... GROVE, ILL. (PRWEB) , ... January 24, 2017 ... ... odor abatement solutions, announced that it has officially formed a distribution partnership with ... equipment for the industrial odor management industry. , Through the agreement, OMI Industries ...
(Date:1/24/2017)... ... ... This Saturday, January 28, the BCFA presents more than 20 local performances including ... musicians Yifan Zhou, Mara McClain & Sarah Nordlund Dennis. Local chefs and restaurants provide ... at Chinese games, crafts & more. Festivities begin at 11:00 am and end at ...
(Date:1/24/2017)... ... , ... The results from the American Cancer Society’s newest report ... cancer patients: incidents of cancer is down as is the likelihood of prostate cancer ... has dropped from its peak of 215.1 in 1991 to 161.2 in 2014 (per ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... unveiled its latest award-winning bottles, designed specifically to optimize the drinking experience for ... Agua is renowned for introducing the world’s first untouched bottled water purposed exclusively ...
(Date:1/24/2017)... ... January 24, 2017 , ... “Choosing Wisdom-Solomon’s ... finances, friendship, marriage, leadership, gossip, prostitution, adultery, anger, and common sense. , ... Judith Coats and Dr. David Coats. In September of 1983, they flew to ...
Breaking Medicine News(10 mins):